Search

Displaying results 2131 - 2140 of 7540 in total
  1. Drug

    Sodium molybdate

    go.drugbank.com/drugs/DB14496
    Approved

    Mixtures: Doctor's Choice Brand for Men, Addamel NProducts: GENERADOR MON TEK99 MO /TC 99 M
  2. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    [L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options. … [L63927] Gedatolisib was approved by the FDA on July 14, 2026, in combination with [fulvestrant], with or without [palbociclib], for adults with HR-positive, HER2-negative locally advanced or metastatic

  3. Drug

    Colistimethate

    go.drugbank.com/drugs/DB01111
    ApprovedInvestigationalVet approved

    Colistimethate is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa. … Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms.

  4. Drug

    Omidubicel

    go.drugbank.com/drugs/DB17132
    ApprovedInvestigational

    It is administered as a single intravenous dose specific to each patient. … In addition, the fact that 39% of the study's cohort were non-White patients highlights the importance of this type of treatment in key demographics with low donor availability.

  5. Drug

    Gemifloxacin

    go.drugbank.com/drugs/DB01155
    ApprovedInvestigational

    Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. … Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia.

  6. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    [L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons … [L64096] It is administered by intrathecal injection, and requires dilution with an accompanying artificial cerebrospinal fluid diluent before administration.

  7. Drug

    Propacetamol

    go.drugbank.com/drugs/DB09288
    Investigational

    [A7892] It is not available in the United States but this prodrug has been widely used in other countries such as France since 1985.[L1505] … [A32051] It is a derivative of [acetaminophen], or paracetamol, with the molecular formula glycine, N, N-diethyl-,4-(acetylamino)phenyl ester.

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  8. Drug

    Arrhenatherum elatius pollen

    go.drugbank.com/drugs/DB10879
    Approved

    Arrhenatherum elatius pollen is the pollen of the Arrhenatherum elatius plant. Arrhenatherum elatius pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Standardized and Non-Standardized Coastal Grasses, Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic Extract
  9. Drug

    mRNA-1345

    go.drugbank.com/drugs/DB18739
    ApprovedInvestigational

    [L53403,L52380] In June 2025, its US indication was expanded to include patients 18-59 years old at increased risk of disease.

  10. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence … [L63808] The FDA approved zidesamtinib on July 22, 2026, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor.